Technology area: Biotechnology & Pharmaceuticals
68 pending office actions • 41 clients • 63 examiners • 38 art units • 0 of 68 (0%) have an AI response strategy ready
HOXIE & ASSOCIATES LLC has 71 pending office actions in Biotechnology & Pharmaceuticals and 2168 career applications. Its resolved allowance rate is 82.3%, with an average of 3.78 office actions per allowance.
The profile combines a substantial current docket with a sizable historical application record. The resolved allowance rate describes completed outcomes, while the office-action average indicates the examination effort associated with matters that reached allowance. These measures give practitioners a basis for evaluating both prosecution results and the likely need for sustained response work.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (6%) |
| §103 only | 8 (12%) |
| §102 only | 1 (1%) |
| §112 only | 15 (22%) |
| Double-patenting only | 4 (6%) |
| Double-patenting + other | 18 (26%) |
| Multi-statute (no §101) | 17 (25%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.5% | +27.0% |
| COLEMAN, BRENDA LIBBY | 2 | 74.8% | +15.7% |
| PECKHAM, RICHARD GRANT | 2 | 68.1% | +36.1% |
| PUTTLITZ, KARL J | 2 | 69.2% | +18.5% |
| SHOWALTER, ALEXANDER KEITH | 2 | 55.4% | +27.3% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| YU, HONG | 1 | 31.1% | +5.7% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548719 | Method of Evaluating the Biofilm Detachment Efficacy of Compositions | SWIFT, CANDICE LEE | 2d overdue |
| 17917337 | USE OF BROMODOMAIN INHIBITORS FOR TREATMENT OF HUNTINGTON'S DISEASE | SIMMONS, CHRIS E | 15d |
| 18873307 | MINOXIDIL ADJUVANT THERAPIES | TRUONG, QUANGLONG N | — |
| 18868080 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | SEUDIEU SEUDIEU, CARINE PATRICIA | — |
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | — |
| 18820161 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | AHVAZI, BIJAN | — |
| 18838517 | PROCESS FOR RECOVERING AND PURIFYING VANILLIN | ARIANI, KADE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | PECKHAM, RICHARD GRANT | 26d |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | COLEMAN, BRENDA LIBBY | 27d |
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | — |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | — |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1626 | 6 |
| 1615 | 4 |
| 1624 | 4 |
| 1642 | 3 |
| 1629 | 3 |
| 1622 | 3 |
| 1641 | 2 |
| 1614 | 2 |
| 1618 | 2 |
| 1625 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §102Other | Final Rejection | — | Pending | Feb 13, 2026 |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | Hutchmed Limited | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Oct 30, 2025 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | Novaliq GmbH | YU, HONG | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Levitasbio, Inc. | MARTIN, PAUL C | 1653 | §103§112DP | Non-Final OA | — | Pending | May 08, 2025 |
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | Shenzhen Oralead Pharma Co., Ltd. | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | — | Pending | Apr 30, 2025 |
| 18873307 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. | TRUONG, QUANGLONG N | 1615 | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18869588 | TREATMENT OF CANCER WITH S1P RECEPTOR AGONISTS | Priothera Limited | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18868772 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | Idorsia Pharmaceuticals Ltd. | KOSACK, JOSEPH R | 3991 | §112 | Non-Final OA | — | Pending | Nov 24, 2024 |
| 18868080 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd. | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §103§112Other | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | P2 Science, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | 18d overdue | Pending | Nov 19, 2024 |
| 18952990 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | Safety Shot, Inc. | MERCIER, MELISSA S | 1615 | §112DP | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18866978 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | KIFLE, BRUCK | 1624 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | Genequantum Healthcare (Suzhou) Co., Ltd. | EVANS, JASMINE AFIYA | 1616 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | Novaliq GmbH | PECKHAM, RICHARD GRANT | 1627 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18847126 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | SCHMITT, MICHAEL J | 1629 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18847121 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18843308 | MODULATORS OF ACKR3 AND USES THEREOF | Stichting VU | SEAMAN, D MARGARET M | 1625 | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18820161 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | Osmo Labs, Pbc | AHVAZI, BIJAN | 1763 | §102§112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18819236 | CRYSTALS | Aeromics, Inc. | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18838517 | PROCESS FOR RECOVERING AND PURIFYING VANILLIN | International Flavors & Fragrances, Inc. | ARIANI, KADE | 1651 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | Alfasigma S.p.A. | KUCKLA, ANNA GRACE | 1626 | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18833346 | NOVEL COMPOSITIONS | Tulex Pharmaceuticals, Inc. | HOLLOMAN, NANNETTE | 1612 | §103§112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18777765 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18729674 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | Friedrich Miescher Institute For Biomedical Research | DHAR, MATASHA | 1632 | §112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18755795 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited | WILLIS, DOUGLAS M | 1624 | DPOther | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18714302 | Rapid T-Cell Manufacturing | Kure Cells, Inc. | EBBINGHAUS, BRIANA NOEL | 1632 | §102§103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18670391 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | JAVANMARD, SAHAR | 1622 | §112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18709201 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | BERRY, LAYLA D | 1693 | §102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18705346 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd. | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18703113 | SILYL ETHER DERIVATIVES OF POLYETHER POLYMERS | P2 Science, Inc. | BAHTA, MEDHANIT W | 1692 | §112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18693766 | FORMULATIONS AND USES OF RESVERATROL | Danstar Ferment AG | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18690068 | GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD | Beijing Genecradle Pharmaceutical Co., Ltd. | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18686381 | IMMUNOGENIC COMPOSITIONS AND THEIR USE | Osivax Belgique | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18290928 | THERAPEUTIC MUTEINS | Institut National De La Santé Et De Al Recherche Médicale (Inserm) | MIDDLETON, DANAYA L | 1674 | §112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18564510 | ANTIBODY SPECIFICALLY BINDING TO ASM PROTEIN | Isu Abxis Co., Ltd. | PRIEST, JESSICA MARIE | 1642 | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Montelino Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 27d | Pending | Nov 08, 2023 |
| 18022051 | BACTERIAL TARGETING VECTOR CARRYING CYTOKINE OR POLYNUCLEOTIDE THEREOF AND USE THEREOF IN TUMOR TREATMENT | Shenzhen Synthetica Pioneering Co., Ltd. | XU, QING | 1656 | §102§103§112Other | Final Rejection | — | Pending | Oct 12, 2023 |
| 18481168 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | RODRIGUEZ-GARCIA, VALERIE | 1600 | §103DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18551396 | METHOD FOR DIAGNOSING DRY MOUTH USING BIOMARKERS | The Regents of the University of California | SITTON, JEHANNE SOUAYA | 1699 | §101§103§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18550088 | THE OXIDATION OF CARBON-HYDROGEN BONDS USING OZONE | P2 Science, Inc. | CUTLIFF, YATE KAI RENE | 1692 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18464129 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | Team Medical, LLC | SHIN, DANA H | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Brightgene Bio-Medical Technology Co., Ltd. | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 14d | Pending | Sep 07, 2023 |
| 18548719 | Method of Evaluating the Biofilm Detachment Efficacy of Compositions | The Ohio State University | SWIFT, CANDICE LEE | 1657 | §101§103§112DP | Final Rejection | 2d overdue | Pending | Sep 01, 2023 |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd. | CHO, DAVID H | 1693 | DP | Final Rejection | 9d | Pending | Sep 01, 2023 |
| 18353653 | VISUAL CONTINUOUS SPATIAL DIRECTED EVOLUTION METHOD | Shenzhen Institutes Of Advanced Technology | BOESEN, CHRISTIAN C | §101§103Other | Non-Final OA | — | Pending | Jul 17, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial82.3% of resolved applications prosecuted by Hoxie & Associates LLC were allowed, across 2,168 applications in USPTO records.
3.78 office actions per allowed application on average.
68 pending office actions as of October 2026, for 41 clients, before 63 examiners in 38 art units.
